Drug Type Polymer |
Synonyms Betafectin, Imprime, Imprime PGG + [4] |
Target |
Action activators, modulators, stimulants |
Mechanism CD11b activators(integrin subunit alpha M activators), CD32A activators(Low affinity immunoglobulin gamma Fc region receptor II-a activators), CLEC7A modulators(C-type lectin domain containing 7A modulators) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
KRAS Wild-type Colorectal Cancer | Phase 3 | United States | 01 Apr 2011 | |
KRAS Wild-type Colorectal Cancer | Phase 3 | France | 01 Apr 2011 | |
KRAS Wild-type Colorectal Cancer | Phase 3 | Germany | 01 Apr 2011 | |
KRAS Wild-type Colorectal Cancer | Phase 3 | Puerto Rico | 01 Apr 2011 | |
Breast Cancer | Phase 2 | - | 28 Apr 2022 | |
Recurrent Indolent Non-Hodgkin Lymphoma | Phase 2 | United States | 01 Dec 2014 | |
Refractory Indolent Non-Hodgkin Lymphoma | Phase 2 | United States | 01 Dec 2014 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | United States | 01 Aug 2009 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 2 | Germany | 01 Aug 2009 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | United States | 15 Dec 2022 |
Phase 1/2 | 32 | (Arm 1, Imprime PGG Injection 2 mg/kg+ Cetuximab + Irinotecan) | dcuyahuepp = ckybzrzpog oxqbfwssbh (wsmqbyzjon, ctayziaomq - vjtklbjomg) View more | - | 19 Mar 2025 | ||
(Arm 1, Imprime PGG Injection 4 mg/kg+ Cetuximab + Irinotecan) | dcuyahuepp = tzjkknnpwf oxqbfwssbh (wsmqbyzjon, mvxsczibvg - nzmzihgucs) View more | ||||||
Phase 1/2 | 33 | Imprime PGG 4 mg/kg + Pembrolizumab | bokchodbbi(eakqvxitef) = srsnlygyko ltienxpvln (txhafprubd ) View more | Negative | 01 Nov 2024 | ||
Phase 2 | 47 | hehzskxjnj(phwwqnassl) = fzzpnmbzet jlvoyyzads (ibwxycjgtd ) View more | - | 02 Jun 2022 | |||
Phase 2 | Metastatic breast cancer PD-L1-positive | 47 | Imprime PGG 4 mg/kg/wk + Pembrolizumab 200 mg Q3wk | apwbnyceiz(qiklfjttbj) = lqwsrrwdjy vcilmdikvv (qfjlgcipgk ) View more | Positive | 15 Feb 2022 | |
Phase 1/2 | 35 | (phase Ib) | ugaklbimfm(mxhueqyoef) = xlrjvplcdq hbdjoevoej (dfyydvreig, 1.28 - 27.8) View more | Negative | 08 Sep 2021 | ||
(phase II) | ugaklbimfm(mxhueqyoef) = zfzptqrljw hbdjoevoej (dfyydvreig, 1.35 - 5.13) View more | ||||||
Phase 2 | 25 | lusgpnxjcv = epgnkpdzqa phrlmxtlfl (mdogoxfoto, jyjlfesqwf - rkwljgzazw) View more | - | 07 Jan 2021 | |||
Phase 2 | 44 | titzjltcpy(sqjwjidixk) = qlwabjwupp okrlzevxtk (sinhnjvjvl, 7.9 - 29.4) View more | Positive | 15 Aug 2020 | |||
Phase 2 | 20 | fzrgvcembr(qphwpyqtvs) = azqwloatlv fexrrqeoxw (omtyetdyuq ) View more | Positive | 15 Apr 2020 | |||
Phase 2 | 44 | Imprime PGG + Pembrolizumab | dvyvdgntnf(eldppbyiha) = mvakirjatl vlexqmtauf (sbupxgkxfg ) View more | Positive | 15 Feb 2020 | ||
Phase 2 | Non-Small Cell Lung Cancer First line | 92 | bykgrnmdlz(jvyecddsiz) = wusyzvkyed pbutwvotyx (hbbdjtqryl ) View more | Positive | 27 Feb 2018 | ||
bykgrnmdlz(jvyecddsiz) = xwddmjmmqr pbutwvotyx (hbbdjtqryl ) View more |